MicroRNA-31: a pivotal oncogenic factor in oral squamous cell carcinoma

Xiaojiao Lin1,4, Weizhou Wu2,4, Yukang Ying1, Jun Luo1, Xuhui Xu1, Linxia Zheng1, Weili Wu1, Suqing Yang1,2✉ and Shankun Zhao3,4✉

© The Author(s) 2022

Oral squamous cell carcinoma (OSCC) continuously constitutes a major challenge for treatment and prognosis due to approximately half of treated OSCC patients dying from locoregional recurrences and distant metastases. MicroRNA-31 (miR-31), an early mammalian miRNA identified, has been gaining importance in the field of OSCC research in recent years. This comprehensive review was conducted for the first time to summarize the current evidence on the association between miR-31 and OSCC. The vast majority of relevant studies (20/21, 95%) demonstrated that miR-31 was an oncogenic factor in the tumorigenesis and progression of OSCC. miR-31 expression is significantly upregulated in plasma, saliva, and tumor tissue of OSCC. miR-31 played an essential role in OSCC development by constituting a complex network with its targeted genes (e.g. RhoA, FIH, ACOX1, VEGF, SIRT3, LATS2, KANK1, and NUMB) and the signaling cascades (e.g. EGF-AKT signaling axis, ERK-MMP9 cascade, Hippo pathway, Wnt signaling, and MCT1/MCT4 regulatory cascade). This review highlights that miR-31 might function as a potential diagnostic, prognostic, and predictive biomarker for OSCC. Further studies are still warranted to better illuminate the clinicopathological features and the molecular mechanisms of miR-31-mediated OSCC development.

Cell Death Discovery (2022)8:140; https://doi.org/10.1038/s41420-022-00948-z

FACTS

• MiR-31 commonly serves as an oncogenic factor in OSCC development.
• MiR-31 level is upregulated in plasma, saliva, and the tumor tissue of OSCC.
• MiR-31 interacts with multiple proteins and pathways that play an essential role in OSCC.

OPEN QUESTIONS

• What is the exact mechanism of MiR-31 in the pathogenesis of OSCC?
• What are the future clinical implications of MiR-31 examination in OSCC?
• Can we develop an effective drug for OSCC patients by targeting MiR-31?

INTRODUCTION

Oral cancer continues to be one of the leading lethal causes worldwide. According to GLOBOCAN 2020, lip and oral cavity cancer accounted for 377,713 (1.96%) new cases and 177,757 (1.79%) deaths globally [1]. Oral cancer is highly frequent in South Central Asia and Melanesia. Common risk factors for oral cancer include betel nut chewing, consumption of alcohol, tobacco use/cigarette smoking, and HPV infection [1, 2]. Oral squamous cell carcinoma (OSCC) is the most frequent type of malignancies, accounting for more than 90% of all oral cancer cases [3]. The overall 5-year survival rate for OSCC was reported at 50–60% [4], 80% for the early stage (T1), and 20–40% at the later stage (T2 or T4) [5]. The therapeutic regimens for OSCC include surgery, radiotherapy, chemotherapy, and immunotherapy. However, approximately half of treated OSCC patients die from locoregional recurrences and distant metastases. Chemotherapy is the main adjuvant therapy for advanced OSCC. However, a chemotherapy commonly does not achieve satisfactory outcomes due to intrinsic and extrinsic resistance, low target selectivity, and serious adverse drugs effects. Motivated by these facts, it is prudent to develop an effective, quick, and non-invasive means to early diagnose and predict the prognosis of OSCC so that minimize the mortality and morbidity of the suffers.

microRNAs (miRNAs) are a class of short, endogenous, non-coding RNA molecules that contain 19-24 nucleotides. miRNAs elicit their biological functions by binding the 3’ untranslated region (UTR) of the target gene mRNA, thus promoting the degradation of the mRNA or leading to translational repression, which eventually implements the post-transcriptional regulation of gene expression [6]. Numerous experimental studies have suggested that miRNAs are involved in the regulation of multiple
cellular biological processes, e.g. proliferation, differentiation, and apoptosis. Thus, the dysregulation of miRNAs has been considered to be associated with various pathologies, including the tumor-igenesis and progression of OSCC. As reported, a majority of miRNAs have been found to show an aberrant expression in OSCC, i.e., miR-503 [7], miR-210 [8], and miR-146 [9]. Among these miRNAs, microRNA-31 (miR-31) is one of the most investigated miRNAs whose expression undergoes significant changes in OSCC. There has been much research evidence on the roles of miR-31 in tumorigenesis and the development of OSCC. A previous clinical study developed by Liu et al. demonstrated that miR-31 in plasma was significantly increased in patients with OSCC as compared to the age and sex-matched control subjects [10]. In line with this finding, a more recent in vitro and in vivo study also showed that the level of miR-31 was aberrantly elevated in OSCC cells and tumor tissues and further indicated that miR-31 gene locus was required to elicit oncogenesis in OSCC [11].

Recently, the crucial effect of miR-31 in OSCC has attracted increasing attention from researchers. In this study, we presented a first attempt to summarize all the evidence on the proposed roles of miR-31 in OSCC development via a comprehensive review. Based on the current knowledge, it may be instructive to help the researchers be conscious of the outstanding prognostic and predictive effects of miR-31 on OSCC.

Overview of miR-31 in cancer
MicroRNA-31 (miR-31), a gene located on chromosome band 9p21.3, was one of the early mammalian miRNAs detected [12]. miR-31 is encoded by a single genomic locus, which can be found in various tissues, cell types, and extracellular exosomes. Consistent with other miRNAs, miR-31 functionally modulates its direct targeted-mRNA via the interaction with the 3′ UTR, constituting the RNA-induced silencing complex thus inducing the silencing of the targeted gene. miR-31 has been found to play role in multiple diseases, e.g. autoimmune diseases, wound healing, and cancer [13]. As reported, miR-31 is among the most commonly varied microRNAs in multiple human malignancies [12], including OSCC [10, 11]. Numerous studies [14] demonstrate that miR-31 participates in cancer pathogenesis and aggressiveness through modulating the target genes. As reported, miR-31 may modulate a series of target genes, including, but not limited to, fibronectin type III domain containing 5 (FNDC5), special AT-rich sequence-binding protein-2 (SATB2), E2F2, large tumor suppressor kinase 2 (LATS2), tensin 1 (TNS1), AT-rich interaction domain 1A (ARID1A), and hypoxia-inducible factor-1 (FIH-1) [15–17]. Commonly, miR-31 is upregulated in the biological processes of cancer [18]. miR-31 expression levels in serum, saliva, urine, and organ tissue can be used as an effective diagnostic and prognostic biomarker of multiple cancers [19, 20]. miR-31 is thought to have high malignant potential because it can dramatically elevate the capability of the migration, growth, and invasiveness of the cancer cells [21]. Currently, miR-31 was proven to be significantly associated with patient survival, response to different treatments, and other clinicopathologic features of multiple cancers, including tumor properties, invasiveness, clinical stage, and metastasis [14, 22]. The above evidence endows miR-31 with an encouraging prospect to be applied as a diagnostic, predictive, and prognostic biomarker in oncological patients. At present, there have been many review articles on the relationship between miR-31 expression and human malignancies, e.g. colorectal cancer, pancreatic cancer, ovarian cancer, prostate cancer [12, 23–26]. However, there is currently no review article that focuses on the
| Study/Reference | Research objects | Role of miR-31 | Involved mechanism | Target gene | Associated pathways | Main findings |
|-----------------|------------------|----------------|-------------------|-------------|---------------------|--------------|
| Liu et al. [10] | OSCC patients, plasma and saliva | Up; Oncogenic | Clinical study | Clinical study | Clinical study | Plasma miR-31 was significantly increased in OSCC patients compared to the control subjects ($P < 0.0001$), while 88% ($38 / 43$) of the OSCC patients showed a significant degree of decrease in miR-31 level after resection ($P < 0.0001$). Saliva miR-31 was elevated in OSCC patients ($P = 0.001$), while 89% ($8/9$) exhibited the decrease level after tumor resection. |
| Liu et al. [27] | Patients plasma and saliva | Up; Oncogenic | Clinical study | Clinical study | Clinical study | Salivary miR-31 was significantly elevated in patients with OSCC at all clinical stages (all $P < 0.05$) compared to the health controls, while the miR-31 expression was significantly reduced after tumor resection; miR-31 was more abundant in saliva than in plasma. |
| Chang et al. [28] | Tissues and oral cells | Up; Oncogenic | Proliferation, migration | RhoA | NA | miR-31 and miR-31* was up-regulated in OSCC tissues, the activity of miR-31*’s activity counteracted the functions of miR-31 during OSCC tumorigenesis. |
| Siow et al. [29] | Patients tissue | Up; Oncogenic | Cell cycle; cytoskeletal remodeling; EMT | Unknown | Regulation of G1/S transition; GM-CSF signaling | miR-31 was significantly increased in OSCC tissue ($P < 0.05$) and significantly associated with TNM staging and site ($P < 0.05$). |
| Lu et al. [30] | Tissues and oral cells | Up; Oncogenic | NA | Unknown | EGF-AKT signaling axis | EGF up-regulated miR-31 expression via the AKT pathway, EGF-AKT-C/EBPβ regulatory axis may underlie miR-31 up-regulation in OSCC. |
| Hung et al. [31] | Tissues and Oral keratinocytes | Up; Oncogenic | Proliferation, migration, and EMT | FIH, hTERT, and VEGF | NA | Increased miR-31 level was observed in oral potentially malignant disorder tissues; miR-31 expression contributed to the acquisition of the EMT by M31OK1 cells; Oral tumorigenesis correlated to the upregulation of miR-31 targeted FIH, hTERT, and VEGF. |
| Kolokythas et al. [32] | Patients tissues | Up; Oncogenic | Clinical study | Clinical study | Clinical study | miR-31-5p was enriched in the tumor epithelium in OSCC compared to benign pathology. |
| Severino et al. [33] | Plasma | Up in non-metastatic samples | Clinical study | Clinical study | Clinical study | miR-31 was over-expressed in non-metastatic samples of OSCC compared with the metastatic samples. |
| Kao et al. [34] | Mouse and cell | Up; Oncogenic | NA | Unknown | EGFR/AKT/S6 | Salivary and plasma miR-31 increased along with the development of tongue carcinogenesis; The increase of salivary miR-31 was higher than in plasma; miR-31 might activate EGFR/AKT/S6 or enhance the oncogenic process for the subsequent tumor induction. |
| Study/Reference          | Research objects | Role of miR-31 | Involved mechanism                                      | Target gene | Associated pathways | Main findings                                                                                                                                 |
|-------------------------|------------------|----------------|---------------------------------------------------------|-------------|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| Cinpolat et al. [35]    | Patients tissues | Up; Oncogenic  | Clinical study                                         | Clinical study | Clinical study      | miR-31 was up-regulated in the tissues of salivary gland tumor group compared to benign group (P = 0.02).                                      |
| Yan et al. [36]         | Patients tissues | Up; Oncogenic  | NA                                                      | Unknown      | NA                  | miR-31 was identified to play essential roles in carcinogenesis of OSCC.                                                                      |
| Lai et al. [37]         | Patients tissues, OSCC cell lines | Up; Oncogenic  | Reprogramming of lipid metabolism; migration, invasion | ACOX1        | ERK-MMP9 cascade ↑ | miR-31-5p was a highly expressed miRNA in OSCC; miR-31-5p-ACOX1-PGE2 axis positively affect the extent of cell motility in correlation with metastatic status of OSCC. |
| Yap et al. [38]         | Patients tissues | Up; Oncogenic  | Clinical study                                         | Clinical study | Clinical study      | Upregulation of miR-31 was found in OSCC in both formalin-fixed paraffin embedded and fresh frozen samples.                                 |
| Kao et al. [39]         | OSCC tissues and cells | Up; Oncogenic  | Glycolytic metabolism, oxidative stress, migration, invasion | SIRT3       | NA                  | miR-31 involved in ROS regulation and OSCC cells invasion by affecting SIRT3 expression; SIRT3 expression reduced the tumorigenicity and disrupted mitochondrial structure of OSCC cells; miR-31 inhibited the respiratory activity and elevated lactate production in OSCC cells; miR-31 was significantly upregulated in OSCC when compared to the controls (P < 0.001). |
| Jakob et al. [40]       | Patients tissues | Up; Oncogenic  | Clinical study                                         | Clinical study | Clinical study      |                                                                                                                                             |
| Jung et al. [41]        | OSCC cell lines and drosophila melanogaster | Down; Tumor-suppressive | Cell cycle and proliferation WLS | Cyclin D1, c-MYC, and Wnt signaling pathway ↓ | miR-31-induced suppression of tissue growth; Overexpression of miR-31 in OSCC cells induced downregulation of WLS, a putative target for miR-31, together contributing to suppress tumor growth, suggesting miR-31 might be a tumor suppressor. |
| Peng et al. [42]        | OSCC tissues and cells | Up; Oncogenic  | Proliferation, migration, invasion, and EMT LATS2 | Hippo signaling pathway ↓ | miR-31 level was markedly increased in OSCC tissues; circ_0000140 negatively associated with miR-31 expression (r² = 0.43, P < 0.001) and positively associated with LATS2 expression (r² = 0.60, P < 0.001). |
| Wang et al. [43]        | OSCC tissues and cells | Up; Oncogenic  | Apoptosis, cisplatin sensitivity KANK1 | Long non-coding RNA CASC2-miR-31-5p/KANK1 axis ↑ | miR-31-5p was upregulated in cisplatin-resistant OSCC tissues and cells, KANK1 acted as a target for miR-31-5p; CASC2 modulated KANK1 expression via sponging miR-31-5p. |
| Kumari et al. [44]      | Patients saliva  | Up; Oncogenic  | Clinical study                                         | Clinical study | Clinical study      | The salivary miR-31 level was significantly higher in the preoperative patients than that of postoperative (P < 0.001). miR-31 might be a potential non-invasive marker to monitor surgery outcomes during postoperative follow-up in patients with OSCC. |
| Study/Reference   | Research objects                                          | Role of miR-31                             | Involved mechanism                                                                   | Associated pathways                                                                                                    | Main findings                                                                                                                                 |
|------------------|-----------------------------------------------------------|--------------------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Chou et al. [11] | OSCC cell and Mouse                                      | Up: Oncogenic                             | Proliferation, migration, invasion                                                    | Hippo-signaling pathway ↓                                                                                               | miR-31 upregulation was required to elicit invasion cascade, which was connected with oncogenesis in OSCC cells, while NUMB was the target of miR-31. Reduced miR-31 expression upregulated MCT1/MCT4 expression in tumors associated with worse survival. |
| Yuan et al. [45] | Patients tissues, mouse, and cell                        | Up: Oncogenic                             | Proliferation, tumorgenesis, M2 macrophages dysfunction                               | LATS2 Hippo pathway ↓                                                                                                  | miR-31 expression was higher in malignant tissues than patients. The expression was elevated in patients with OSCC. The involved mechanisms mainly included proliferation, migration, invasion, apoptosis, cell cycle, epithelial-to-mesenchymal transition (EMT), cytoskeletal remodeling, reprogramming of lipid metabolism, glycolytic metabolism, oxidative stress, and M2 macrophages dysfunction. The direct targets for miR-31 included ras homolog family member A (RhoA), factors inhibiting HIF (FIH), human telomerase reverse transcriptase (Htter), acyl-CoA oxidase 1 (ACOX1), vascular endothelial growth factor (VEGF), prostaglandin E2 (PGE2), silent information regulator 3 (SIRT3), large tumor suppressor kinase 2 (LATS2), KN motif and ankyrin repeat domain-containing protein 1 (KANK1), wntless (WLS), and NUMB endocytic adaptor protein (NUMB). The associated signaling cascades included GM-CSF signaling, EGF-AKT signaling axis, ERK-MMP9 cascade, Hippo pathway, Wnt signaling pathway, and MCT1/MCT4 regulatory cascade. |

**Table 1. continued**

| Study/Reference | Research objects                                           | Role of miR-31 | Involved mechanism                           | Associated pathways                                                                                                      | Main findings                                                                                                                                                           |
|-----------------|------------------------------------------------------------|----------------|-----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Siow et al. [29]| OSCC and squamous cell carcinoma, blood and lymphatic family member A (PLAT), epithelial-to-mesenchymal transition (EMT), factors inhibiting HIF (FIH) | Up: Oncogenic | Proliferation, migration, invasion            | LATS2 Hippo pathway ↓                                                                                                  | miR-31 upregulation was observed in OSCC in both formalin-fixed and formalin-fixed tumor tissues, suggesting its role in tumor progression. |

**Clinical significances of miR-31 IN OSCC**

There are fourteen included studies that provided detailed clinical information of miR-31 expression level in OSCC. All the eligible clinical studies reported that miR-31 was upregulated in OSCC patients.

**miR-31 expression was higher in malignant tissues than benign tissues**

Significant histopathological alterations of miR-31 expression observed in the tissue sections between OSCC and benign tissue can intuitively reflect the critical roles of miR-31 in OSCC development and progression. All the included studies that provided the information on the expression of miR-31 in pathological sections consistently suggested that the level of miR-31 was up-regulated in OSCC tissues. But the association between miR-31 and the clinical characteristics of OSCC was a bit different among different studies. Siow et al. [29] found that miR-31 level was significantly associated with TNM staging and site of OSCC (all P < 0.05). Kolokythas et al. [32] reported that miR-31 expression was enriched in the tumor epithelium in OSCC compared to benign pathology. miR-31 was also found to be correlated with the metastatic status of OSCC [37]. A previous study indicated that miR-31 upregulation was observed in OSCC in both formalin-fixed...
paraffin-embedded and fresh frozen samples [38]. Moreover, miR-31 was also identified to be associated with the chemotherapy resistance of OSCC treatments. For example, Wang et al. [43] found that miR-31-5p was upregulated in cisplatin-resistant OSCC tissues. The above evidence demonstrated that high expression of miR-31 was closely associated with the clinicopathologic features of OSCC, e.g. TNM staging, tumor site, and chemotherapy resistance.

The plasma and saliva miR-31 was significantly increased in patients with OSCC, which was associated with the clinical features of OSCC

As reported, increased expression of miR-31 was not only observed in the OSCC tissues, but also the plasma and saliva of an OSCC patient. Numerous studies have demonstrated that miRNAs have the potential to be detected as effective biomarkers in body fluids. Liu et al. [10] reported that plasma miR-31 was dramatically elevated in OSCC patients compared to the control subjects (P < 0.0001), while 88% (38/43) of the OSCC patients showed a significant degree of decrease in miR-31 level after resection (P < 0.0001). Consistently, the authors also found that saliva miR-31 was elevated in OSCC patients compared to the non-cancer subjects (P = 0.001), while 89% (8/9) exhibited the decreased level after tumor resection. In the subsequent study [27], the authors further indicated that the salivary miR-31 was significantly increased in patients with OSCC at all clinical stages (all P < 0.05), while the miR-31 expression was remarkably reduced after tumor resection. Besides, Liu et al. demonstrated that miR-31 was more abundant in saliva than in plasma. Kumari et al. [44] revealed that the salivary miR-31 level was significantly higher in the preoperative patients than that of postoperative (P < 0.001), suggesting miR-31 might be a potential non-invasive marker to monitor surgery outcomes during postoperative follow-up in patients with OSCC. Higher levels of miR-31 level have frequently been found in OSCC patients than cancer-free individuals, while miR-31 expression in metastatic- and non-metastatic OSCC is rarely reported. A study [33] conducted in Brazil showed that plasma miR-31 was overexpressed in non-metastatic samples of OSCC than that of metastatic samples. This study pinpointed the fact that plasma miR-31 was higher in OSCC patients than the healthy controls, while its expression was higher in patients with non-metastatic OSCC when compared to those with metastasis.

Molecular mechanisms of miR-31 in OSCC

Due to the aforementioned clinical studies having suggested a causal relationship between miR-31 level and OSCC, a better understanding of the biological functionings of miR-31 and its underlying mechanisms in OSCC tumorigenesis and development is profound for the investigators. miR-31 was up-regulated in the majority of OSCC and thus it was thought to play an oncogenic role in OSCC.

Cell cycle regulation underlies the effect of miR-31 in OSCC tumorigenesis

Cell cycle control is one of the crucial cancer-related pathways in the development of multiple malignancies, including OSCC. Altered expression of miRNAs can result in the inhibition or promotion of cell cycle arrest and cell death. Experimental studies have demonstrated that miR-31 was involved in the progression and metastasis of various types of cancers by regulating the cell cycle [46, 47]. Siow et al. [29] reported that elevation of miR-31 expression was correlated with the clinical features in OSCC. The carcinogenic mechanisms of miR-31 in OSCC were supposed to be the regulation of the cell cycle via the G1/S transition. Jung et al. [41] also indicated that the cell cycle might participate in the action of miR-31 in OSCC development. However, in contrast to Siow et al.’s findings, Jung et al. demonstrated that miR-31 might serve as a tumor suppressor in OSCC due to the level of miR-31 could induce the suppression of OSCC tumor growth. The authors speculated that the underlying mechanisms of miR-31 inhibiting OSCC might be associated with the down-regulation of the driving factors of the cell cycle, e.g. Cyclin D1 and c-MYC. In addition, this study also suggested that wntless (WLS), a putative target for miR-31, together contribute to OSCC suppression by regulating the Wnt signaling pathway [41].

Roles of EMT in miR-31-regulated OSCC

EMT, a widely accepted mechanism for cancer development, occurs frequently during the pathological process associated with tumorigenesis and cancer progression towards metastasis [14]. Migratory and invasive behaviors of the cancer cells may encounter an enhancement after a shift towards the mesenchymal state of the malignant cells, which are characterized by the abnormal expression of EMT-related molecules and the shape changes altering into spindle [48]. Numerous studies suggest that miR-31 promotes the oncogenic effect on multiple cancers through the EMT process [49]. In the present review, three studies [29, 31, 42] demonstrated that EMT might be one of the key pathomechanisms underlying the miR-31-mediated OSCC. All these studies indicated the expression of miR-31 was increased in OSCC patients compared to the non-tumoral individuals. Hung et al. [31] reported that up-regulation of miR-31 contributed to the acquisition of the EMT by M31OK1 cells. They further found that oral tumorigenesis might correlate to the elevation of miR-31 targeted genes, e.g. factors inhibiting HIF (FIH), human telomerase reverse transcriptase (hTERT), and vascular endothelial growth factor (VEGF). Peng et al. [42] revealed that miR-31 expression was markedly increased in OSCC tissues, while circ_0000140 negatively associated with miR-31 level (r² = 0.43, P < 0.001) and positively associated with large tumor suppressor kinase 2 (LAT52) expression (r² = 0.60, P < 0.001). The authors also found that the Hippo signaling pathway played an essential role in this action. The above evidence indicated that EMT might greatly contribute to tumorigenesis and the progression of miR-31-associated OSCC.

miR-31 functions as an oncogenic factor by increasing the proliferative, migratory, and invasive capacities of the OSCC cells

Proliferation, migration, and invasion strongly correlate with a malignant phenotype. According to a large body of experimental studies, multiple miRNAs play crucial roles in cancer development by strengthening the proliferative, migratory, and invasive capacities of the cancer cells [50, 51]. Chang et al. [28] reported that miR-31 promoted the proliferation and migration of oral cancer cells by targeted RhoA. In agreement with Chang et al.’s findings, Hung et al. [31] also demonstrated that up-regulated miR-31 could induce OSCC tumorigenesis via the enhancement of proliferation and migration. There were also several studies [37, 39] indicating the oncogenic effects developed by miR-31 were largely dependent on the promotion of migration and invasion of the oral cancer cells. Lai et al. [37] reported that miR-31-5p positively affected the extent of cell motility in correlation with the metastatic status of OSCC by targeting ACOX1 and upregulating ERK-MMP9 cascade. Kao et al. [39] found that miR-31 was involved in OSCC cells migration and invasion by affecting SIRT3 expression. Besides, there have been many studies [11, 42] that suggested that the roles of miR-31 in OSCC might be associated with the elevation of proliferation, migration, and invasion of the OSCC cells which mainly were mediated the targeted genes. Peng et al. [42] revealed that circ_0000140 was negatively associated with miR-31 expression (r² = 0.43, P < 0.001) and positively associated with the miR-31-targeted LAT52 expression (r² = 0.60, P < 0.001). A more recent study [11] demonstrated that miR-31 gene locus was required to elicit oncogenesis in OSCC cells. NUMB, a direct target of miR-31, was negatively associated with the metastatic status of OSCC and positively associated with the miR-31-targeted LATS2 expression (r² < 0.001). The authors also found that the Hippo signaling pathway played an essential role in this action. The above evidence indicated that EMT might greatly contribute to tumorigenesis and the progression of miR-31-associated OSCC.
Other potential mechanisms underlay miR-31-mediated OSCC

As shown in Table 1, in addition to the above-supposed mechanisms, other pathomechanisms included cytoskeletal remodeling, reprogramming of lipid metabolism, glycolytic metabolism dysfunction, oxidative stress injury, anti-apoptosis, M2 macrophages dysfunction, and the dysfunction of affected signaling pathways. Both glycolytic metabolism and oxidative stress are considered to involve in the pathogenesis and progression of multiple malignancies [52]. Kao et al. [39] suggested that miR-31 participated in OSCC development by disrupting the mitochondrial structure and increasing lactate production in OSCC cells. Cisplatin is one of the common-used first-line chemotherapy regimens for treating OSCC but usually fails because of chemoresistance [53]. miR-31-5p upregulation was found in cisplatin-resistant OSCC, which was considered to be associated with the anti-apoptosis characteristic of miR-31 [43]. Tumor-associated macrophages are the crucial elements of the tumor microenvironment. M2 macrophage-derived exosomes were found to promote cancer progression by delivering miRNA [54]. Yuan et al. [45] demonstrated that macrophage-derived exosomal miR-31-5p might inhibit the tumor suppressor LATS2, thus facilitating the progression of OSCC via suppressing the Hippo signaling pathway. Various lines of evidence suggest that the basic leucine zipper transcription factor CCAAT/enhancer binding protein \( \beta \) (C/EBP\( \beta \)) is an oncogenic factor [55]. The epidermal growth factor receptor (EGFR) signaling pathway is considered to play an important role in driving the oncogenesis of OSCC by triggering various proteins and intracellular signaling networks (i.e., AKT) [56, 57]. Lu et al. [30] reported that EGF might upregulate the level of miR-31 expression through the AKT signaling cascade in a malignant phenotype of OSCC. The author further found that the C/EBP\( \beta \) cascade could increase the expression of miR-31 and there was a significant correlation between C/EBP\( \beta \) and miR-31 expression during OSCC pathogenesis.

Figure 2 illustrated the detailed potential molecular mechanisms of miR-31 in OSCC. Figure 3 summarized the main findings of this review via a diagram.

CONCLUSION AND PERSPECTIVES

To the best of our knowledge, the present comprehensive review is the first study that summarizes all the current evidence on the association between miR-31 and OSCC. The vast majority of relevant studies demonstrate that miR-31 is an oncogenic factor in the tumorigenesis and progression of OSCC. miR-31 expression is significantly upregulated in plasma, saliva, and tumor tissue of OSCC, which enhances the malignant phenotypes of OSCC. This review highlights that miR-31 may function as a potential therapeutic target owing to its essential role in OSCC development. miR-31 interacts with multiple signaling cascades by...
binding to its targeted proteins, constituting a complex network that promotes OSCC. In the future, a better understanding of the association of miR-31 with clinicopathological features and the molecular mechanisms could provide insights into the crucial role of miR-31 in driving OSCC malignant transformation, which may favor the development of miR-13-based diagnostic, prognostic, and predictive biomarker for OSCC.

DATA AVAILABILITY

The data used to support the findings of this study are available from the corresponding author upon request.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.

2. Gupta S, Gupta R, Sinha DN, Mehrotra R. Relationship between type of smokeless tobacco & risk of cancer: a systematic review. Indian J Med Res. 2018;148:56–76.

3. Bimmadi NQ, Basile JR. Perineural invasion in oral squamous cell carcinoma: a discussion of significance and review of the literature. Oral Oncol. 2011;47:1005–10.

4. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993;328:184–94.

5. Al RN, Elmabrouk N, Abu KR, Mkaaddmi S, Bizzi Z, Hamdoon Z. The role of differentially expressed salivary miRNA in oral squamous cell carcinoma. A systematic review. Arch Oral Biol. 2021;125:105108.

6. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509–24.

7. Yamana K, Inoue R, Sakata J, Nakashima H, Arita H, et al. Extracellular vesicles derived from radioresistant oral squamous cell carcinoma cells contribute to the acquisition of radioresistance via the miR-503-3p-BAK axis. J Extracell Vesicles. 2021;10:e12169.

8. Bigagli E, Locatelli LG, Di Stadio A, Maggiore G, Valdarnini F, Bambi F, et al. Extracellular vesicles miR-21 as a potential biomarker for diagnosis and survival prediction of oral squamous cell carcinoma patients. J Oral Pathol Med. 2021. https://doi.org/10.1111/jop.13263.

9. Ghuwawela S, Ghatak D, Das S, Roy D, Das P, Butti R, et al. MiRNA-146a/akt/beta-catenin activation regulates cancer stem cell phenotype in oral squamous cell carcinoma by targeting CD24. Front Oncol. 2021;11:651692.

10. Liu CJ, Kao SY, Tu HF, Tsai MM, Chang KW, Lin SC. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis. 2010;16:360–4.

11. Chou CH, Chang CF, Yang CC, Liu YC, Chang SR, Chang KW, et al. miR-31-NUMB cascade modulates monocarboxylate transporters to increase oncogenicity and lactate production of oral carcinoma cells. Int J Mol Sci. 2021;22:11731.

12. Lauria EM, Kallioniemi A. The diverse role of miR-31 in regulating cancer associated phenotypes. Genes Chromosomes Cancer. 2013;52:1103–13.

13. Stepicheva NA, Song JL. Function and regulation of microRNA-31 in development and disease. Mol Reprod Dev. 2016;83:654–74.

14. Moloudizargari M, Rahmani J, Schwendimann R, Fabian P, Smerdova T, Kno...
45. Yuan Y, Wang Z, Chen M, Jing Y, Shu W, Xie Z, et al. Macrophage-derived exosomal miR-31-5p promotes oral squamous cell carcinoma tumourigenesis through the large tumor suppressor 2-mediated hippo signalling pathway. J Biomed Nanotechnol. 2021;17:822–37.

46. Zhang WW, Ming XL, Rong Y, Huang CQ, Weng H, Chen H, et al. Diagnostic value investigation and bioinformatics analysis of miR-31 in patients with lymph node metastasis of colorectal cancer. Anal Cell Pathol (Amst). 2019;2019:9740475.

47. Wang J, Li B, Wang C, Luo Y, Zhao M, Chen P. Long noncoding RNA FOXD2-AS1 promotes glioma cell cycle progression and proliferation through the FOXD2-AS1/miR-31/CDK1 pathway. J Cell Biochem. 2019;120:19784–95.

48. Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev Mol Cell Biol. 2019;20:69–84.

49. Yu F, Liang M, Huang Y, Wu W, Zheng B, Chen C. Hypoxic tumor-derived exosomal miR-31-5p promotes lung adenocarcinoma metastasis by negatively regulating SATB2-reversed EMT and activating MEK/ERK signaling. J Exp Clin Cancer Res. 2021;40:179.

50. Gui CP, Liao B, Luo CG, Chen YH, Tan L, Tang YM, et al. circCHST15 is a novel prognostic biomarker that promotes clear cell renal cell carcinoma cell proliferation and metastasis through the miR-125a-5p/EIF4EBP1 axis. Mol Cancer. 2021;20:179.

51. Lee YJ, Kang CW, Oh JH, Kim J, Park JP, Moon JH, et al. Downregulation of miR-216a-5p and miR-652-3p is associated with growth and invasion by targeting JAK2 and PRKX1 in GH-producing pituitary tumours. J Mol Endocrinol. 2021;68:51–62.

52. Mossenta M, Busato D, Dal Bo M, Toffoli G. Glucose metabolism and oxidative stress in hepatocellular carcinoma: role and possible implications in novel therapeutic strategies. Cancers (Basel). 2020;12:1668.

53. Florea AM, Busselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2011;3:1351–71.

54. Wei K, Ma Z, Yang F, Zhao X, Jiang W, Pan C, et al. M2 macrophage-derived exosomes promote lung adenocarcinoma progression by delivering miR-942. Cancer Lett. 2022;526:205–16.

55. Du S, Yang Z, Lu X, Yousuf S, Zhao M, Li W, et al. Anoikis resistant gastric cancer cells promote angiogenesis and peritoneal metastasis through C/EBPbeta-mediated PDGFbeta autocrine and paracrine signaling. Oncogene. 2021;40:5764–79.

56. Berndt A, Buttner R, Guhne S, Gleinig A, Richter P, Chen Y, et al. Effects of activated fibroblasts on phenotype modulation, EGFR signalling and cell cycle regulation in OSCC cells. Exp Cell Res. 2014;322:402–14.

57. Xie H, Ma Y, Li J, Chen H, Xie Y, Chen M, et al. WNT7A promotes EGF-induced migration of oral squamous cell carcinoma cells by activating beta-catenin/ MMP9-mediated signaling. Front Pharmacol. 2020;11:98.

ACKNOWLEDGEMENTS
This work was supported by The Science and Technology Planning Project of Taizhou City, Zhejiang Province (Nos. 1902ky43 and 20ywb40); The Medical and Health Science and Technology Plan Project of Zhejiang Province (No. 2022KY1402); The High-level Hospital Construction Research Project of Maoming People’s Hospital.

AUTHOR CONTRIBUTIONS
L-XJ, W-WZ, and Y-YK: Study Designed, Project development, and Data Collection; L-J and X-XH: Data Collection, Conceptualization; Z-LX and W-WL: Methodology and Investigation; Y-SQ and Z-SK: Original Draft and Revised Manuscript.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Suqing Yang or Shankun Zhao.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022